Literature DB >> 8751541

Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival?

M A Finan1, S DeCesare, J V Fiorica, R Chambers, M S Hoffman, R C Kline, W S Roberts, D Cavanagh.   

Abstract

Two hundred twenty-nine patients with Stage IB cervical cancer treated with radical hysterectomy were assigned to the new FIGO substages IB1 (n = 181) and IB2 (n = 48) based on clinical tumor diameter. Our purpose was to determine the impact of the new staging system for IB1 and IB2 cervical cancer on nodal status and survival. Additionally, we analyzed the morbidity of radical hysterectomy in light of the new staging system. The complications were similar between the two groups. Para-aortic lymphadenectomy was the only independent predictor of complications (P = 0.00026). Stage IB2 patients did have a significantly worse 5-year survival (72.8%) when compared with IB1 (90.0%) (P = 0.0265). Multivariate stepwise logistical regression analysis indicated that the new staging system did not have an independent impact on survival. Stage acts through nodal status in its impact on survival. Positive lymph nodes, tumor diameter, and Ponderal Index are all independent predictors of survival (P = 0.0001). Patients with Stage IB2 carcinoma of the cervix undergoing radical hysterectomy showed no significant increase in morbidity when compared with patients with Stage IB1 disease treated with the same procedure.

Entities:  

Mesh:

Year:  1996        PMID: 8751541     DOI: 10.1006/gyno.1996.0206

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Survival Outcomes of Patients With Stage IB3 Cervical Cancer Who Undergo Abdominal Radical Hysterectomy Versus Radiochemotherapy.

Authors:  Zhiqiang Li; Qing Yang; Jianxin Guo; Guoqiang Liang; Hui Duan; Shaoguang Wang; Min Hao; Wentong Liang; Donglin Li; Xuemei Zhan; Qinghuang Xie; Jinghe Lang; Ping Liu; Chunlin Chen
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

2.  Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.

Authors:  E R Nijhuis; H W Nijman; K A Oien; A Bell; K A ten Hoor; N Reesink-Peters; H M Boezen; H Hollema; A G J van der Zee
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

3.  Experience in stage IB2 cervical cancer and review of treatment.

Authors:  Taner Turan; Burcu Aykan Yıldırım; Gökhan Tulunay; Nurettin Boran; Ferah Yıldız; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

4.  Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.

Authors:  J Visser; H W Nijman; B-N Hoogenboom; P Jager; D van Baarle; E Schuuring; W Abdulahad; F Miedema; A G van der Zee; T Daemen
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

5.  Radical hysterectomy with pelvic lymphadenectomy: indications, technique, and complications.

Authors:  Rachel A Ware; John R van Nagell
Journal:  Obstet Gynecol Int       Date:  2010-09-01

6.  Radical surgery for stage IB2/IIA2 cervical cancer: A large retrospective study.

Authors:  Fang Zhou; Xuedong Tang; Zhuyan Shao; Xi Chen; Wen Gao; Chenyan Fang; Zejia Wang; Ping Zhang; Tao Zhu; Huarong Tang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

7.  Discovery of DNA methylation markers in cervical cancer using relaxation ranking.

Authors:  Maté Ongenaert; G Bea A Wisman; Haukeline H Volders; Alice J Koning; Ate Gj van der Zee; Wim van Criekinge; Ed Schuuring
Journal:  BMC Med Genomics       Date:  2008-11-24       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.